{
  "source": "PA-Notification-Zilxi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1342-4\nProgram Prior Authorization/Notification\nMedication Zilxi® (minocycline)\nP&T Approval Date 12/2020, 12/2021, 12/2022, 1/2024\nEffective Date 4/1/2024\n1. Background:\nZilxi is FDA approved for the treatment of inflammatory lesions of rosacea in adults. This\nformulation of minocycline has not been evaluated in the treatment of infections.\n2. Coverage Criteria:\nA. Initial Authorization\n1. Zilxi will be approved based on the following criterion:\na. Diagnosis of rosacea with inflammatory lesions.\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Zilxi will be approved for continuation of therapy based on the following criterion:\na. Documentation of a positive clinical response to therapy\nAuthorization will be issued for 12 months.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Step Therapy and Supply limits may be in place.\n4. References:\n1. Zilxi [package insert]. Bridgewater, NJ: Vyne Pharmaceuticals Inc; September 2022.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Zilxi\nChange Control\n12/2020 New program\n12/2021 Annual review. Updated reference.\n12/2022 Annual review. Updated reference.\n1/2024 Annual review. No changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}